Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Roth Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by stock analysts at Roth Capital in a report released on Monday,Benzinga reports. They currently have a $12.00 price objective on the stock. Roth Capital’s price target would indicate a potential upside of 143.70% from the company’s current price.

A number of other brokerages also recently weighed in on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research note on Monday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, August 12th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Coya Therapeutics Stock Performance

NASDAQ COYA traded up $0.05 during trading hours on Monday, hitting $4.92. 55,156 shares of the company traded hands, compared to its average volume of 188,206. The business’s 50-day moving average is $4.90 and its 200-day moving average is $4.67. The stock has a market capitalization of $115.52 million, a price-to-earnings ratio of -4.60 and a beta of 0.61. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Analysts predict that Coya Therapeutics will post -1.44 EPS for the current year.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Long Corridor Asset Management Ltd acquired a new stake in Coya Therapeutics during the second quarter worth approximately $227,000. Cetera Investment Advisers increased its stake in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after purchasing an additional 8,000 shares during the period. Occudo Quantitative Strategies LP bought a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $66,000. Millennium Management LLC bought a new stake in Coya Therapeutics in the 4th quarter valued at $121,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $47,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.